AngioLab Inc
251280
Company Profile
Business description
AngioLab Inc is a biotechnology company. It is developing pharmaceuticals and health functional foods based on the inhibition of angiogenesis. The group is developing natural products and antibody-based pharmaceuticals.
Contact
65, 122, 159, Techno 3-ro
Yuseong-gu
Gwanpyeong-dong, Hanshin S Mecca
Daejeon
KORT: +82 428675785
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
16
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
Shares are cheap despite rebounding share price, yet risks remain.
stocks
ASX listed media giant drives strong earnings growth
Digital growth drives earnings beat for media share.
stocks
ASX real estate platform outperforms yet questions remain
Valuation remains a key concern despite strong August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,424.30 | 13.10 | -0.14% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,880.11 | 212.08 | 0.83% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,879.12 | 1,272.41 | 1.94% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,233.40 | 16.20 | -0.18% |
| SSE Composite Index | 3,952.54 | 12.50 | 0.32% |